- Home
- REI vs NTHI Comparison
REI vs NTHI Comparison
Compare REI & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REI | NTHI |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 195.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | REI | NTHI |
|---|---|---|
| Price | $0.92 | $8.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 77.5K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,790,652.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $3.20 |
| 52 Week High | $1.55 | $25.00 |
Technical Indicators
Market Signals| Indicator | REI | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 50.30 |
| Support Level | $0.86 | $8.46 |
| Resistance Level | $0.97 | $9.75 |
| Average True Range (ATR) | 0.04 | 0.87 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 48.40 | 81.06 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).